Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Cholangiocarcinoma 6Carcinoma, Transitional Cell 5Acrocephalosyndactylia 5Neoplasm Metastasis 3Gastrointestinal Neoplasms 3Breast Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor, Miscellaneous 1Solid Tumor 1Sarcoma 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Myeloproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lung Neoplasms 1Locally Advanced Unresectable Gastric Cancer 1Liposarcoma 1Hematologic Neoplasms 1Glioma 1Glioblastoma 1

Interventions

Rituximab 78Cyclophosphamide 76fludarabine phosphate 45Peripheral Blood Stem Cell Transplantation 41Mycophenolic Acid 39Tacrolimus 35Whole-Body Irradiation 33Radiotherapy 29Busulfan 29Cyclosporine 27Antilymphocyte Serum 27Etoposide 25Filgrastim 24Methotrexate 22Melphalan 22Lenalidomide 15Cytarabine 15Cord Blood Stem Cell Transplantation 14fludarabine 13Methylprednisolone 13Bortezomib 13orelabrutinib 12Dexamethasone 12sargramostim 11obinutuzumab 11Sirolimus 9Carmustine 9venetoclax 8Vincristine 8Prednisone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, B-Cell, Marginal Zone × pemigatinib × Clear all
NCT06300528 2025-12-03

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

University of Utah

Phase 2 Recruiting
27 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡